Research news
Becker muscular dystrophy:
- 14 March 2012
Update on BIO-NMD: A research project looking into Duchenne, Becker, Ullrich and Bethlem muscular dystrophies An update on the progress of BIO-NMD - an EU funded project searching for biomarkers - 14 February 2012
Clinical trial plans announced for utrophin drug for Duchenne Summit has outlined plans to test a drug for Duchenne and Becker muscular dystrophies - a phase 1 trial will start soon and results should be available before the end of this year. - 13 February 2012
Update on ataluren extension trial for Duchenne PTC Therapeutics expects that most study centres involved in the ataluren extension trial in the UK, continental Europe, Israel and Australia will open between March and June this year. - 19 December 2011
Summit secures funding for utrophin drug for Duchenne Summit plc has secured £1 million worth of funding from several US-based charities to manufacture a new formulation of a potential drug for Duchenne and Becker muscular dystrophies and conduct a Phase 1 clinical trial. - 30 November 2011
Ataluren extension trial for Duchenne about to start PTC Therapeutics has affirmed their commitment to develop ataluren to treat boys with Duchenne muscular dystrophy and announced progress in starting an extension trial in the UK, Europe, Israel and Australia. - 26 October 2011
National Conference 2011 - research workshop Highlights from the research workshop at the National Conference 2011 where scientists discussed their research projects. - 18 October 2011
Nine cutting-edge new research projects awarded funding We are proud to announce the addition of nine exciting new projects to our portfolio which aim to increase understanding of and develop treatments for muscle diseases. - 6 October 2011
Have your say about medical research A study is asking people aged 12 to 21 who have muscular dystrophy about their attitudes towards medical research and taking part in it. - 9 September 2011
PTC Therapeutics to take over development of ataluren for Duchenne Genzyme and PTC Therapeutics have restructured their collaboration for the development of the drug ataluren for Duchenne muscular dystrophy. - 5 May 2011
Utrophin drug shows promise for Duchenne and Becker muscular dystrophies Research in mice, part-funded by the Muscular Dystrophy Campaign, has shown the remarkable potential of a drug that increases the amount of the protein called utrophin in the muscles.
